Tucatinib
Sign in to save this workspacePrimary targets: ERBB2_HER2 · FDA status: FDA Approved
Selectivity scorecard
KISS
99.75
Gini
0.652
CATDS
0.054
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Tucatinib. Strongest target: JAK1 at 92.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | JAK1 | 92.7% | 7.3% |
| 2 | RIPK4 | 36.0% | 64.0% |
| 3 | JAK2 | 33.6% | 66.4% |
| 4 | TYK2 | 29.5% | 70.5% |
| 5 | AURORA_A | 28.4% | 71.6% |
| 6 | STK38_NDR1 | 20.5% | 79.5% |
| 7 | COT1_MAP3K8 | 18.9% | 81.1% |
| 8 | CDK1_CYCLIN_E | 17.7% | 82.3% |
| 9 | MEKK6 | 17.6% | 82.4% |
| 10 | PKCIOTA | 17.3% | 82.7% |
| 11 | WNK3 | 17.2% | 82.8% |
| 12 | TRKB | 16.4% | 83.6% |
| 13 | CDK4_CYCLIN_D1 | 16.4% | 83.6% |
| 14 | CDK4_CYCLIN_D3 | 15.6% | 84.4% |
| 15 | LRRK2 | 15.0% | 85.0% |
| 16 | TAOK3_JIK | 14.8% | 85.2% |
| 17 | FAK_PTK2 | 14.6% | 85.4% |
| 18 | CDK1_CYCLIN_B | 14.3% | 85.7% |
| 19 | CAMK4 | 14.1% | 85.9% |
| 20 | AURORA_B | 13.7% | 86.3% |
Selectivity landscape
Where Tucatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Tucatinib.
Atlas insights for Tucatinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.853 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.840 |
| TCGA-CV-7424-01A-11R-2081-07 | — | 0.838 |
| SRR10899984 | — | 0.838 |
| C3L-03726 | — | 0.835 |
Annotations
Sign in to read and post annotations.
Loading…